Michael Zimmerman, MD, will tell you that he is impatient, with about as much fanfare as someone might mention they’re left-handed. He chose emergency medicine partly because of that trait: the ER moves fast, emergency medics get to travel in helicopters, and nobody makes … Read more
When a large-scale vaccine trial needed to move fast, Velocity delivered — not once, but twice, across two continents. In the United States, Velocity was the sole site network selected to enroll participants for the trial. Across just 10 sites, the team enrolled 1,000 … Read more
By Sweta Pittala, VP, Technology Portfolio Management At a Glance Responding to Requests for Proposal (RFPs) is one of the most labor-intensive processes in clinical trial operations. Velocity’s Feasibility Agent automates and augments that process, drawing on years of data on site performance from … Read more
Congratulations to Ipsen on positive Phase IIIb results from the ELSPIRE trial evaluating IQIRVO® (elafibranor) in patients with Primary Biliary Cholangitis (PBC). The trial met its primary endpoint with statistical significance, with 85% of patients treated with IQIRVO achieving ALP normalization versus 23% on … Read more
By Nick Spittal, Chief Operations Officer, Velocity Clinical Research How many times have you heard the term AI this week? Sponsors are investing in it, CROs are building for it, and tech vendors are popping up left, right, and center to sell it. Sites … Read more
By Andrew Reina, Chief Revenue Officer I spent the better part of two decades on the CRO side of clinical research, which gives you a particular vantage point. You see how sponsors evaluate site networks, what they ask for, and (more tellingly) what they … Read more
There is a phrase William Beacham, MD reaches for when people ask how he ended up an OB-GYN: congenital gynecologist. It was his father’s speciality, too, and his grandfather was a physician. Four of his father’s five brothers also went into medicine. So, by … Read more
Since 2020, Velocity Clinical Research has supported trials that contributed to 61 FDA-approved products — and we couldn’t be more proud of what that represents. Those 61 FDA-approved products span an extraordinary range of therapeutic areas: cardiovascular disease, obesity and diabetes, Alzheimer’s disease, respiratory … Read more
Congratulations to Zydus Therapeutics on the US FDA granting Priority Review to their New Drug Application for saroglitazar for the treatment of Primary Biliary Cholangitis (PBC)! Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG — Velocity Principal Investigator and EPICS-III Study Investigator — was featured … Read more
Given his time again, Robert Buynak, MD, FACP, may well be a train driver — but as a young man, he wasn’t sure how to go about it. Academically gifted, he was raised in the true spirit of the American Dream: “My mom’s family … Read more
Shishir Khetan, MD has always been interested in science and how the body works. His mother was an OB-GYN and, while she never practiced in the U.S., would talk about medicine here and there — a discourse that helped influence his own interest. “My … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was featured in the recent Mirum Pharmaceuticals announcement that the VISTAS Phase 2b study of volixibat met its primary endpoint in patients with primary sclerosing cholangitis (PSC) and cholestatic pruritus. PSC is a rare, chronic liver disease … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.